Abstract
Astaxanthin (AST) is related to apoptosis but the details of the mechanism of how AST makes apoptosis is not clear. The present study investigated apoptotic effects of AST to SKBR3, a breast cancer cell line in detail. Cell viability assay showed cellular proliferation and morphological changes of the cells were observed under AST treatment. FACS analysis indicated that AST blocked cell cycle progression at G0/G1, suppressed proliferation dose-dependently, and induced apoptosis of the cells. The apoptosis of the cells by AST was further demonstrated through the decreased expression level of mutp53 and cleaved a PARP-1 fragment, respectively. In addition, AST induced the intrinsic apoptosis of the cells by activation of Bax/Bcl2, cleaved caspase-3, and cleaved caspase-9 as well as the phosphorylation of ERK1/2, JNK, and p38. Furthermore, AST decreased production of intracellular reactive oxygen species as well as modulated expressions of superoxide dismutases and Pontin, an anti-apoptotic factor. Co-immunoprecipitation assay revealed AST reduced interaction between Pontin and mutant p53. Taken together, these studies proved that AST regulates the expression of apoptotic molecules to induce intrinsic apoptosis of the cells, suggesting AST therapy might provide an alternative for improving the efficacies of other anti-cancer therapies for breast cancer.
Highlights
Breast cancer is the most frequently diagnosed cancer in women [1]
We investigated detailed mechanisms of apoptosis caused by AST with exploring the multiple molecules related apoptosis including mutp53, superoxide dismutases (SODs), mitogen-activated protein kinase (MAPK), and Pontin
Cell viabilities were tested to determine whether AST affects the growth of SKBR3 cells
Summary
Breast cancer is the most frequently diagnosed cancer in women [1]. Death rates for female breast cancer are 36% lower than peak reported rates [2]. Breast cancer is still expected to account for almost 30% of newly diagnosed cancers in women [2]. The current anti-cancer agents including paclitaxel, cisplatin, 5-fluorouracil, and others used to treat breast cancer are limited because their cytotoxic effects extend to normal tissues [3]. For this reason, therapeutic natural products that inhibit cancer cell growth but have low toxicity profiles are being investigated as candidate therapeutics [4]. Studies on drug development have focused on reducing tumor volumes and on regulating various apoptosis signaling pathways [5]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.